Neoadjuvant-only enfortumab vedotin in VOLGA may spare neuropathy, according to Alexandra Drakaki, MD, PhD; Guru P. Sonpavde, MD, urged caution.
Alexandra Drakaki, MD, PhD
Advertisement
Articles by Alexandra Drakaki, MD, PhD
Alexandra Drakaki, MD, discusses guidance from a modified Delphi panel on managing peripheral neuropathy in patients with locally advanced or metastatic urothelial carcinoma receiving enfortumab vedotin.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Q&A: Suzanne B. Merrill, MD, FACS, on perioperative therapy in MIBC
3
Pasritamig combination yields 73% PSA response rate in phase 1 mCRPC study
4
Survey: Service members and veterans with NMIBC report barriers to treatment access
5